Valuation: Amgen Inc.

Market Cap 220B 333,558B 193B 182B 166B 310B 21,062B 313B 2,176B 844B 10,729B 824B 806B 34,858B P/E 2026 *
25.6x
P/E 2027 * 23x
Enterprise Value 261B 396,595B 229B 216B 198B 369B 25,042B 372B 2,587B 1,003B 12,756B 980B 959B 41,445B EV / Sales 2026 *
6.7x
EV / Sales 2027 * 6.33x
Free-Float
99.77%
Yield 2026 *
2.48%
Yield 2027 * 2.62%
1 day+0.60%
1 week+9.25%
Current month-4.42%
1 month-6.14%
3 months+21.92%
6 months+28.36%
Current year+31.13%
1 week 20,200
Extreme 20200
22,170
1 month 19,910
Extreme 19910
23,810
Current year 15,920
Extreme 15920
23,810
1 year 12,320
Extreme 12320
23,810
3 years 6,637
Extreme 6637
23,810
5 years 1,283.33
Extreme 1283.333333
23,810
10 years 273.67
Extreme 273.666666
23,810
Manager TitleAgeSince
Chief Executive Officer 63 30/04/2012
Director of Finance/CFO 62 12/05/2010
Chief Tech/Sci/R&D Officer 57 31/05/2023
Director TitleAgeSince
Chairman 63 31/12/2012
Director/Board Member 65 31/12/2011
Director/Board Member 71 31/12/2011
Change 5-day change 1-year change 3-year change Capi.($)
+0.60%+9.25% - - 220B
+2.68%+3.87%+58.22%+114.68% 1,026B
+0.56%+1.27%+53.29%+68.65% 649B
+0.02%+0.99%+19.10%+73.58% 468B
+0.06%+0.25%+37.03%+45.71% 352B
+1.16%+4.10%+21.99%+29.39% 271B
-0.24%+2.18%+10.14%+12.26% 256B
-0.01%+7.89%+41.57%+51.68% 220B
-1.11%+1.36%+30.85%+99.56% 188B
+0.30%-7.19%-32.43%-60.56% 170B
Average +0.13%+1.26%+26.64%+48.33% 399.9B
Weighted average by Cap. +0.18%+1.26%+37.30%+67.68%

Financials

2026 *2027 *
Net sales 38.94B 59,166B 34.23B 32.24B 29.46B 55.06B 3,736B 55.54B 386B 150B 1,903B 146B 143B 6,183B 40.31B 61,250B 35.43B 33.37B 30.5B 57B 3,867B 57.5B 400B 155B 1,970B 151B 148B 6,401B
Net income 8.58B 13,038B 7.54B 7.1B 6.49B 12.13B 823B 12.24B 85.06B 32.99B 419B 32.22B 31.51B 1,363B 9.39B 14,272B 8.26B 7.78B 7.11B 13.28B 901B 13.4B 93.12B 36.11B 459B 35.27B 34.5B 1,491B
Net Debt 41.49B 63,037B 36.46B 34.35B 31.39B 58.66B 3,980B 59.18B 411B 159B 2,028B 156B 152B 6,588B 35.82B 54,423B 31.48B 29.65B 27.1B 50.65B 3,436B 51.09B 355B 138B 1,750B 134B 132B 5,687B
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
24/09/26 ARS 21,860.00 +0.60% 862
23/09/26 ARS 21,730.00 -0.50% 10,288
22/09/26 ARS 21,840.00 +4.30% 2,808
21/09/26 ARS 20,940.00 +1.95% 1,605
18/09/26 ARS 20,540.00 +2.04% 2,145
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
406.09USD
Average target price
389.22USD
Spread / Average Target
-4.15%

Quarterly revenue - Rate of surprise